This result is partially consistent with a previous finding that the frequency of Tregs (CD4 + CD25highFOXP3+) among total T cells determines the outcome of blinatumomab therapy in patients with B-ALL [33]. This evidence concerns the gene CD4 and acute lymphoblastic leukemia.